A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
about
An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma.Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogenEfficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceClinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancerErbB3 downregulation enhances luminal breast tumor response to antiestrogens.Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.Fulvestrant and male breast cancer: a pooled analysis.Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidenceLEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
P2860
Q34507441-FA90E8E1-53ED-4E9A-A063-656F29E271C1Q34855692-DAE26EF1-B782-4FA2-BBE5-4D4CB4EF1C11Q34880376-C0B70C67-06FF-4FB4-AC89-56BA8000CC58Q35631641-EB69F35D-EAE0-437C-99CA-670D5528E7ADQ36059078-AA005EEB-7801-40F4-93C6-2AF67436E2C2Q36250585-460CB601-454A-40AD-AE3F-C8F029D9D249Q36287107-F1178A12-308E-4C76-8F69-14E11BCE48A3Q37200831-6F9CC856-06BA-4BBA-B676-AABCA802B50CQ39027480-55B4FD0D-7CC2-4DFF-8660-1CD8B04BB29CQ41677482-F7A776A4-ABB9-4791-BDDD-932A5F1D9141Q49988930-0424261F-8CFD-48B9-850B-E7C63D933990Q54981847-88CFC5D2-1E5F-4E1F-9F05-4E384ACB9168Q57107345-000D6C3C-57DC-4732-89F0-5CAEBFE1A9A0Q57291547-A908596B-ECA4-4B83-93E5-722D260AEE21
P2860
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A phase II neoadjuvant trial o ...... ceptor positive breast cancer.
@ast
A phase II neoadjuvant trial o ...... ceptor positive breast cancer.
@en
type
label
A phase II neoadjuvant trial o ...... ceptor positive breast cancer.
@ast
A phase II neoadjuvant trial o ...... ceptor positive breast cancer.
@en
prefLabel
A phase II neoadjuvant trial o ...... ceptor positive breast cancer.
@ast
A phase II neoadjuvant trial o ...... ceptor positive breast cancer.
@en
P2093
P2860
P50
P1476
A phase II neoadjuvant trial o ...... ceptor positive breast cancer.
@en
P2093
Amanda Beyer
Jian Huang
Krystal Sexton
Mothaffar Rimawi
Richard Elledge
Susan Hilsenbeck
Suzanne Fuqua
Wei Yen Cai
Yee L Tham
P2860
P2888
P304
P356
10.1007/S10549-011-1679-8
P407
P577
2011-07-27T00:00:00Z